ERBB2 and breast carcinoma: HER-2 + breast cancers are more susceptible to metastasis (particularly metastasis to the central nervous system and viscera) and are a crucial risk factor for a diagnosis of metastatic breast cancer (stage IV), leading to poorer clinical outcomes and prognosis25and is, therefore, an important therapeutic target in breast cancer.